XHKG2172
Market cap659mUSD
Dec 27, Last price
8.87HKD
1D
0.34%
1Q
3.50%
IPO
-63.80%
Name
MicroPort NeuroTech Ltd
Chart & Performance
Profile
MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial arterial stent system to treat intracranial atherosclerotic disease; and Bridge, a rapamycin target eluting vertebral artery stent system to treat cerebral atherosclerotic stenosis. In addition, it offers Neurohawk, a stent thrombectomy device; Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
Income | |||||
Revenues | 665,624 21.61% | 547,350 42.99% | 382,799 72.49% | ||
Cost of revenue | 485,837 | 432,075 | 285,409 | ||
Unusual Expense (Income) | |||||
NOPBT | 179,787 | 115,275 | 97,390 | ||
NOPBT Margin | 27.01% | 21.06% | 25.44% | ||
Operating Taxes | 27,470 | 20,352 | 7,733 | ||
Tax Rate | 15.28% | 17.66% | 7.94% | ||
NOPAT | 152,317 | 94,923 | 89,657 | ||
Net income | 145,548 -768.73% | (21,765) -190.05% | 24,170 -46.63% | ||
Dividends | (344,002) | ||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
Debt | |||||
Debt current | 23,786 | 24,725 | 27,993 | ||
Long-term debt | 98,934 | 145,763 | 191,403 | ||
Deferred revenue | 19,136 | 18,124 | |||
Other long-term liabilities | 35,567 | 7,894 | 3,253 | ||
Net debt | (985,651) | (812,942) | (577,412) | ||
Cash flow | |||||
Cash from operating activities | 153,778 | 223,798 | 157,406 | ||
CAPEX | (202,603) | (47,945) | (57,980) | ||
Cash from investing activities | (233,159) | (344,523) | (186,790) | ||
Cash from financing activities | (33,276) | 329,537 | 200,746 | ||
FCF | 322,082 | (45,753) | (50,829) | ||
Balance | |||||
Cash | 1,084,358 | 1,134,703 | 593,287 | ||
Long term investments | 24,013 | (151,273) | 203,521 | ||
Excess cash | 1,075,090 | 956,062 | 777,668 | ||
Stockholders' equity | 260,460 | 107,860 | 60 | ||
Invested Capital | 1,474,718 | 1,471,597 | (48,073) | ||
ROIC | 10.34% | 13.34% | 61.66% | ||
ROCE | 10.36% | 7.30% | 8.18% | ||
EV | |||||
Common stock shares outstanding | 582,658 | 517,543 | 582,658 | ||
Price | 12.24 -46.67% | 22.95 | |||
Market cap | 7,131,734 -39.96% | 11,877,612 | |||
EV | 6,148,829 | 11,077,518 | |||
EBITDA | 235,879 | 171,976 | 129,113 | ||
EV/EBITDA | 26.07 | 64.41 | |||
Interest | 3,460 | 99,277 | 45,200 | ||
Interest/NOPBT | 1.92% | 86.12% | 46.41% |